TenSixty Biosciences

Our pipeline

A portfolio built from what biology reveals.

TenSixty is advancing a platform-derived oncology portfolio with programs spanning discovery, modality selection, and early IND-enabling work.

Origin TenSixty discovery platform
Focus Investigational oncology therapeutics
Portfolio Lead, follow-on, and discovery programs

Pipeline of epitope-defined oncology therapeutics

One program in early IND-enabling work, a second in modality selection, and multiple platform-derived binder programs.

  1. TSB-001

    First-in-class antibody-drug conjugate in solid tumors.

    Broad solid tumors

    Xenograft efficacy · NHP safety · CMC progress

    Current work: early IND-enabling, including xenograft efficacy, NHP safety, and CMC progress

  2. TSB-101

    Best-in-class antigen.

    SCLC / neuroendocrine tumors

    Epitope solves clinical liability of previous Phase 2 program. Fully optimized binder, in modality selection.

    Current work: modality selection

  3. Therapeutic Binding

    Programs 3–5

    Broad + indication-specific solid-tumor opportunities

    Advancing through target validation and early optimization.

    Current work: advancing through target validation and early optimization.

  4. Emerging portfolio

    Differentiated epitopes

    Broad + indication-specific opportunities

    Additional targets prioritized for new binder discovery campaigns

    Current work: discovery queue

  1. 01 Target + epitope definition
  2. 02 Binder series
  3. 03 Biological validation
  4. 04 Lead optimization
  5. 05 Therapeutic formatting
  6. 06 Efficacy + safety
  7. 07 IND-enabling
  8. 08 Clinic
Completed package Active

Early discovery stages are directional; final program nomenclature and therapeutic formats remain subject to optimization.

Connect with TenSixty

A portfolio designed to grow with the science.

Start a conversation